Withdrawal of non-binding proposal

26^th Aug 2015

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

HbA1c testing at the point-of-care: Comparison against international quality standards

Nurses from the University of Arkansas Study Abroad program using DiaSpect Tm in Ghana

EKF at Medic East Africa - Nairobi 2018

EKF to highlight new Glycated Albumin assay kit at AACC 2018

EKF Diagnostics, the global in vitro diagnostics company, announces that on Booth #3880 at the AACC 2018 Clinical Lab Expo it will be highlighting a new Stanbio Chemistry Glycated Albumin (GA) assay kit and its newly FDA cleared DiaSpect Tm hemoglobin point of care analyzer. Located in Chicago, IL, from July 31^st to August 2^nd, AACC is the world’s largest exposition for clinical laboratory products and services.